AIM
SCLN

Acrospire Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Acrospire Investment Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,956
Closed -$77K – 2023
2017
Q2 		$77K Buy
6,956
+1,320
+23% +$13.2K 0.07% 443
2017
Q1 		$55K Sell
5,636
-7,994
-59% -$79.8K 0.05% 863
2016
Q4 		$147K Buy
13,630
+848
+7% +$8.48K 0.06% 629
2016
Q3 		$131K Buy
12,782
+8,375
+190% +$91.2K 0.09% 352
2016
Q2 		$58K Sell
4,407
-4,953
-53% -$64.9K 0.04% 948
2016
Q1 		$103K Buy
+9,360
New +$83.2K 0.07% 311

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's SCLN Position: Q3 2017 in Review

Acrospire Investment Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 6,956 shares — an estimated $77K sold.

Acrospire Investment Management first reported a position in SCLN in Q1 2016 and held it in 6 quarters. The position peaked at $147K in Q4 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Acrospire Investment Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 6,956 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $77K.
  • Acrospire Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Sciclone Pharmaceuticals Inc position peaked at $147K in Q4 2016.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.